Therapy Areas: Respiratory
Hoth Therapeutics reports positive interim results for HT-001 topical therapy
25 June 2025 - Hoth Therapeutics Inc (NASDAQ: HOTH), a US-based clinical-stage biopharmaceutical company developing targeted therapies for rare and serious inflammatory conditions, announced on Tuesda...
Merck reports positive Phase 3 results for WINREVAIR in pulmonary arterial hypertension
23 June 2025 - Merck & Co, Inc (NYSE: MRK), a research-intensive biopharmaceutical company, announced on Monday that its Phase 3 HYPERION study evaluating WINREVAIR (sotatercept-csrk) in adults re...
FDA approves Dupixent as first targeted therapy for rare skin disease bullous pemphigoid
20 June 2025 - French healthcare company Sanofi S.A. (Euronext Paris:SAN) (Nasdaq:SNY) announced on Friday that the US Food and Drug Administration has approved Dupixent (dupilumab) as the first targe...
Dizal completes enrolment in sunvozertinib vs. platinum doublet phase III study
20 June 2025 - Chinese biopharmaceutical company Dizal announced on Thursday the completion of patient enrolment for its WU-KONG28 clinical trial in non-small cell lung cancer (NSCLC).WU-KONG28 is a m...
MAIA Biotechnology signs master clinical supply agreement with Roche to advance combination cancer therapies
18 June 2025 - MAIA Biotechnology Inc (NYSE American: MAIA) announced on Wednesday that it has entered into a master clinical supply agreement with Roche to support future studies evaluating the combi...
UCB announces BIMZELX (bimekizumab-bkzx) three-year data at EULAR 2025
12 June 2025 - Biopharmaceutical company UCB (EBR:UCB) announced on Wednesday new three-year data from Phase 3 trials, and their open-label extensions, investigating BIMZELX (bimekizumab-bkzx) in adul...